# US 2021/0171586 A1 · Peptides having reduced toxicity that stimulate cholesterol efflux

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171586 A1
- Document ID: US20210171586A1
- Status: Published application
- Kind: A1
- Application number: 17/016,541
- Filed: 2020-09-10
- Published: 2021-06-10
- Earliest claimed: 2013-03-15
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: John K. Bielicki; Jan Johansson; Waleed Danho
- Web page: https://patentgrep.com/patent/US20210171586A1

## CPC

- C07K 14/435: from animals; from humans
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/544: {Phospholipids}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/775: Apolipopeptides
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A method for mediating cholesterol efflux in a human patient diagnosed as having dementia or at risk of having dementia, and having at least one ApoE4 allele, said method comprising administering to said human a polypeptide having cholesterol efflux activity, wherein the polypeptide comprises an amino acid sequence that is an amphipathic α-helix that has a non-polar surface and a polar surface, wherein the polar surface comprises charged and uncharged amino acid residues at the lipid-water interface, wherein the amino acid sequence:
has at least 60% identity to SEQ ID NO:1; and
comprises a citrulline, or an uncharged analog of citrulline that has a modified R group or modified backbone, but retains the chemical structure of citrulline and maintains a salt-bridge configuration in the α-helix, at one of the three positions 3, 14, and 23 as determined with reference to SEQ ID NO:1; an uncharged amino acid residue at the second of the three positions 3, 14, and 23; and an uncharged amino acid residue or a positively charged residue at the third of the three positions 3, 14, and 23;
comprises an aliphatic amino acid at positions 2, 6, 10, 11, 12, 13, 16, 17, 20, 21, 22, and 24 as determined with reference to SEQ ID NO:1;
comprises a positively charged amino acid at position X5;
comprises a polar uncharged amino acid at position X4; and
comprises an acidic amino acid residue at positions 1, 7, 8, 15, 18, and 19 as determined with reference to SEQ ID NO:1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises a citrulline at two of the three positions 3, 14, and 23; and an R or K at the third position.

### Claim 25 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises an uncharged amino acid at the second and third of the three positions 3, 14, and 23.

### Claim 26 (depends on 23)

The method of claim 23, wherein the α-helix amino acid sequence is 24 amino acids in length and further comprises a position 25 and 26, wherein position 25 is K or N and position 26 is S or Y.

### Claim 27 (depends on 25)

The method of claim 25, wherein the amino acid sequence has Q, N, L, V, I, or A at at least one of the three position 3, 14, or 23.

### Claim 28 (depends on 27)

The method of claim 27, wherein the amino acid sequence has Q or N at at least one of the three position 3, 14, or 23.

### Claim 29 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises an amino acid residue at two of the three positions 3, 14, and 23 that are independently selected from Q, N, L, V, I, or A.

### Claim 30 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises R or K at one of the three positions 3, 14, and 23.

### Claim 31 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises a citrulline at positions 3 and 14 and an R or K at position 23.

### Claim 32 (depends on 23)

The method of claim 23, wherein the aliphatic amino acids at positions 2, 6, 10, 11, 12, 13, 16, 17, 20, 21, and 24 are independently selected from the group consisting of L, V, A, and I.

### Claim 33 (depends on 31)

The method of claim 31, wherein the amino acid sequence comprises an aliphatic amino acid independently selected from the group consisting of L, I, and V at positions 10, 13, 16, and 20.

### Claim 34 (depends on 23)

The method of claim 23, wherein the amino acid sequence comprises SEQ ID NO:1 or SEQ ID NO:2.

### Claim 35 (depends on 23)

The method of claim 23, wherein the polypeptide further comprises a protecting group.
